Business Context and Reporting Period
This Form 8-K is a current report filed by Ra Medical Systems, Inc. (NYSE American: RMED) on October 4, 2022. The filing primarily addresses a joint press release with Catheter Precision, Inc. ("Catheter") regarding a new patent application and provides updates on the ongoing proposed merger between the two entities.
Key Financial Metrics
This filing is a qualitative report on corporate events and does not contain specific financial performance data (revenue, profit, cash flow, or margins) for the reporting period. The document references financial statements filed in previous reports (specifically the September 12, 2022, 8-K and the June 30, 2022, 10-Q) for detailed financial metrics regarding both Ra Medical and Catheter Precision.
Material Changes and Events
- Patent Filing: Catheter Precision has filed a method-of-use U.S. patent application for its VIVO™ (View Into Ventricular Onset) technology.
- Merger Status: The proposed stock-for-stock reverse merger between Ra Medical and Catheter Precision remains active. Under the terms of the Merger Agreement, Catheter will become a wholly owned subsidiary of Ra Medical.
- Regulatory Filings: A preliminary proxy statement regarding the merger was filed with the SEC on September 23, 2022. A definitive proxy statement is expected to be filed subsequently.
Guidance, Outlook, and Risks
Outlook and Management Commentary: The combined company is expected to focus on the cardiac electrophysiology market. Management anticipates the merger will close before the end of 2022, subject to closing conditions including shareholder approval from both companies.
Risks and Contingencies:
- Closing Conditions: The merger is contingent on satisfying specific conditions, including a minimum prevailing stock price for Ra Medical and a required Net Cash amount at closing. If Ra Medical's stock price drops below certain levels, the merger consideration for Catheter stockholders may be adversely impacted.
- Forward-Looking Statements: Actual outcomes may differ due to uncertainties in consummating the merger, accessing capital markets, and maintaining stock exchange listing status.
- External Factors: Risks are amplified by the ongoing COVID-19 pandemic, economic uncertainty, and stock market volatility.
Investor Verification Checklist
- Verify the status of the Definitive Proxy Statement and the timeline for the shareholder vote on the merger.
- Review the minimum prevailing stock price condition for Ra Medical to assess the risk of the merger consideration being reduced or the deal failing.
- Examine the Net Cash requirements at closing as detailed in the Merger Agreement to understand capital market access risks.
- Consult the September 12, 2022, Form 8-K (Exhibits 99.2 through 99.8) for detailed financial statements and risk factors specific to Catheter Precision.
- Confirm the details of the VIVO™ patent application filed by Catheter Precision.